Movement Alert｜GRAIL, Inc. Pre-Market Rise 7.82% in Pre-Market Trading, FDA panel support and a sharp UBS target increase lifted sentiment

Market Focus10-20

On October 20, GRAIL, Inc. rose 7.82% in Pre-Market Trading, trading at $131.99 per share, with turnover of $23,500.

The main catalyst was a favorable regulatory read-through for Galleri, followed by UBS raising its price target to $175 from $105 while maintaining a buy rating, reinforcing expectations for FDA approval and commercialization.

Background details show Galleri previously received supportive votes from the FDA advisory committee: 10 to 0 on safety, 6 to 4 on efficacy, and 7 to 2 with one abstention on benefit-risk for use in adults aged 50 and older. Earlier briefing materials had indicated the FDA debate had narrowed to product positioning and labeling rather than major safety concerns, which helped strengthen the market's confidence in the approval path.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment